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Abstract Alzheimer’s disease, responsible for the vast
majority of dementia cases in the elderly population, is
caused by accumulation of toxic levels of amyloid b pep-
tide (Ab) in the brain. Neprilysin is a major enzyme
responsible for the degradation of Ab in vivo. We have
previously shown that elevation of neprilysin levels in the
brain delays the deposition of Ab -plaques in a mouse
model of amyloidosis and that lack of neprilysin leads to
increased Ab generation and to signs of incipient neuro-
degeneration in mouse brains. This study was designed to
test whether low brain levels of neprilysin affect the
amyloid pathology or perturb the learning and memory
performance of mice. Double-mutated mice carrying a
targeted depletion of one allele of Mme, the gene encoding
neprilysin, and over-expressing human amyloid precursor
protein (APP), exhibited a reinforced amyloid pathology in
comparison with their APP transgenic littermates. More-
over, in contrast to their parental lines, these mice were
impaired in the Morris water maze learning and memory
paradigm and showed facilitated extinction in the
conditioned taste aversion test. These data suggest that
even a partial neprilysin deficiency, as is found during
aging, exacerbates amyloid pathology and may impair
cognitive functions.
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Introduction
Accumulation of Ab in the brain is viewed as the primary
cause of Alzheimer’s disease (AD) pathogenesis. Ab
accumulation is proposed to result from an imbalance
between Ab production and clearance and to induce the
formation of neurofibrillary tangles [1]. The hippocampal
formation is one of the first areas affected by AD and
hippocampal CA1 and CA3 neurons are instrumental for
learning and memory in rodents, nonhuman primates, and
humans [2–5]. The finding that familial AD is caused by
mutations in genes encoding the amyloid precursor protein
(APP) and presenilins, leading to high production of the Ab
peptides in the brain, has established the importance of
over-production of Ab in AD pathophysiology. Conse-
quently, mouse models were generated that produce Ab
pathology in an age-dependent manner. In contrast, a
higher production rate of Ab has not been found in spo-
radic AD, which comprises more than 90% of AD cases.
Therefore, the cause of accumulation of Ab in sporadic
cases is likely to be a deceleration of Ab degradation [6, 7].
Neprilysin, a member of the metalloprotease family, was
identified as the major physiological Ab -degrading
enzyme in the brain [8, 9]. Neprilysin levels in AD brain
regions with high plaque content have been shown to be
approximately half high as the levels found in control brain
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areas with low or moderate plaque burden [10, 11] and
furthermore correlated inversely with amyloid load in
mouse brains [12]. Mechanistically, the presence of nep-
rilysin at presynaptic sites was shown to be of particular
importance in protecting synapses from Ab -derived syn-
aptotoxicity [13]. We have recently demonstrated that
higher brain neprilysin activity delayed the deposition of
amyloid plaques in a mouse model of amyloidosis,
whereas, neprilysin deficiency led to Ab accumulation and
amyloid deposition in mouse brains [14, 15].
The objectives of this study were to determine whether
low brain levels of neprilysin affect Ab concentrations and
amyloid plaque pathology in the brains of transgenic mice
over-expressing human Ab, and whether altered amyloid
pathology reduces the performance of these mice in
behavioral tests. We report here that even a reduction of
brain neprilysin activity to half of normal levels induced an
accelerated accumulation of Ab in mouse brains associated
with significant impairments in hippocampal-dependent
and independent cognitive tasks.
Experimental Procedures
Mice
Both parental mouse lines, with targeted depletion of the
neprilysin gene [16] or the J20 mouse line with transgenic
neuronal over-expression of human APP (APPtg) [17], were
crossbred for more than 20 generations with the C57BL/6
background. Mice were housed under a light cycle of 12 h,
with free access to dry food pellets and water, and were
weaned at 3 weeks of age. Cross-breeding of the mouse lines
was performed by breeding male APPtg mice with female
mice heterozygous for neprilysin depletion to generate wild-
type (WT), APPtg, mice heterozygous for neprilysin defi-
ciency (NEP-) and double-mutated mice heterozygote for
neprilysin deficiency and over-expressing human APP
(NEP-APPtg). The presence of the neprilysin knock-out
versus WT allele and the APP transgene were determined as
previously described [14, 17, 18].
First mouse groups were tested in the open field and
Morris water maze (MWM) behavioral tests, and then were
analyzed by biochemical and immunohistochemical
methods. A second group of mice was tested in the con-
ditioned taste aversion (CTA) test. All experiments were
performed following national and cantonal regulations and
procedures as approved by the cantonal ethics committee.
Behavioral Studies
A total of 48 2 year-old mice (n = 9–14 per genotype),
including balanced numbers of male and female subjects,
were subjected to first round of behavioral testing. After
assessing activity in an open field arena, mice were sub-
jected to the MWM test, which measures hippocampus-
dependent spatial learning and memory. Finally, a second
group of mice, originating from the same breeding pairs
(n = 10 per genotype, containing male and female mice,
24 ± 1 months of age), were subjected to the CTA test.
Morris Water Maze
A modified MWM protocol was employed as described
previously [2]. Briefly, training and testing of mice were
performed under 12 lux diffuse light in a circular pool
constructed from white polypropylene (diameter 150 cm,
wall height 50 cm), filled with opaque water to a height of
16 cm and maintained at 24–26C. In the cued or visible
platform learning, mice were trained for 2 days (six trials
per day) to find a 16 cm 9 16 cm target platform of white
wire mesh, which was placed 0.5 cm above the surface of
water and the position of which was changed with each
trial. Subsequently, to examine the spatial learning, the
platform was submerged 0.5 cm below the water surface in
the NW, NE, SE or SW quadrant 35 cm from the pool wall.
Each mouse was released to the pool from different starting
points and was trained to locate the platform, which was
maintained in the same position for an individual mouse,
over 4 days with six trials per day separated by 30–60 min
intervals and each trial lasting maximally 120 s. About
24 h after completion of training, mice were subjected to a
probe trial of 30 s without the goal platform to test spatial
retention. Animals were tracked using a Noldus Etho-
Vision 3.0 video-tracking system (www.noldus.com) at
576 9 768 pixels spatial resolution and 4.167 Hz sampling
frequency. Raw XY coordinates were transferred to cus-
tom-developed public domain software Wintrack [21]
(www.dpwolfer.ch/wintrack) for further analysis. Spatial
selectivity during the probe trial was assessed using: (1)
percentage time spent in a circular zone centered on the
trained goal and comprising one-eighth of the pool surface
(target zone) versus control zones in the other quadrants,
and (2) the number of crossings over the target area and
respective control annuli of 16 cm diameter.
Conditioned Taste Aversion Test (CTA)
Water-deprived mice (n = 10 per genotype) were housed
individually and were trained over four consecutive days to
drink from two drinking tubes for 20 min in the morning
and 10 min in the afternoon, with a 4 h inter-trial interval
[14, 18]. The fluid intake for each mouse was determined
by weighing the drinking tubes before and after each trial.
On the conditioning day, mice were allowed to drink for
20 min from only one tube, which was filled with a 0.5%
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saccharin solution (Fluka, Buchs, Switzerland) (condi-
tioned stimulus). Mice were then administered a 0.14 M
LiCl solution (at 0.2% of body weight, ip) as the nausea-
inducing agent (unconditioned stimulus) 40 min later.
About 48 h after the conditioning trial, animals were sub-
jected to the first preference choice test (retrieval trial),
which constituted presentation of two drinking tubes, one
containing 0.5% saccharin and one containing water
(choice test) for 20 min. The aversion coefficient was
calculated as the percentage of saccharin consumption
compared with the total fluid intake. This parameter cor-
relates inversely with conditioned learning and memory
performance. This test was repeated once per week over
four consecutive weeks. Finally, the normal taste sensi-
tivity of mouse groups was determined by testing the
natural aversion towards a bitter taste by offering the mice
0.02% quinine solution (Fluka, Buchs, Switzerland) or
water [22, 23].
Biochemical Analysis
Following behavioral testing, 7–8 mice per genotype were
randomly chosen for biochemical analysis of brain tissue.
Mice were perfused transcardially with ice cold PBS,
whole brains were removed, followed by removal of the
cerebellum and olfactory bulbs. Brains were first cut sag-
ittally and then at bregma level dividing each hemisphere
into a frontal region and the caudal brain tissue containing
the hippocampus. The frontal parts and one hippocampus-
containing sample derived from each brain were frozen
immediately. The remaining caudal sample of each brain
was fixed for 48 h in 4% paraformaldehyde at 4C, washed
several times in PBS and embedded in paraffin. The pres-
ence of amyloid plaques was determined in coronal
sections including the hippocampus at interaural level
-1.5 mm to bregma, utilizing the 4G8 monoclonal anti-
body (Seretec) recognizing both human and murine Ab as
described [19]. The second sample of caudal brain tissue,
containing the other hippocampus, was weighed and placed
in ice-cold buffer (1:15 w/v) containing 100 mM Tris (pH
8.0), 150 mM NaCl, 2% SDS and complete protease
inhibitor cocktail (Roche), then homogenized at 1,000 rpm
using a Potter S homogenizer. Brain homogenates were
then centrifuged at 100,000g for 1 h at 4C. The superna-
tant was collected and the remaining pellet was dissolved
in 70% formic acid (1:3 w/v). The concentrations of Ab40
and Ab42 were measured in the brain homogenates using
commercially available kits measuring both human and
murine Ab species (Wako Pure Chemical Industries, Ltd.,
Osaka, Japan) according to the manufacturer’s instructions.
In addition, neprilysin enzymatic activity was measured
in the frontal brain tissues, following homogenization in a
buffer containing 100 mM Tris (pH 8.0) and 150 mM
NaCl, according to published methods [19, 20]. Back-
ground absorbance readings were established using brain
homogenates (n = 4) prepared from age-matched neprily-
sin knock-out mice [16].
Statistical Analysis
Data were collected by colleagues unaware of the genotypes
of the mice. For behavioral tests, groups were always trained
and tested in parallel and identically. Statistical analysis of
biochemical and CTA data was performed using one way
analysis of variance (ANOVA) and significant main effects
of genotype were further analyzed using Fisher’s PLSD post-
hoc test. For analysis of MWM performance, the data of all
groups including males and females, were analyzed using a
3-way factorial ANOVA model with the between-subject
factors of APPtg? (APPtg vs. WT), neprilysin heterozy-
gosity (NEP- vs. WT) and sex. No gender-dependent effects
were found. Therefore, final analysis was performed using a
two-way ANOVA without the gender factor. In order to fit
the factorial ANOVA model, training variables were aver-
aged over all training trials. For selected variables, the
ANOVA model was complemented by the within-subject
factors of time (blocks of two subsequent trials) and place
(trained vs. average of non-trained sites), in order to assess
learning rates and place preferences. To further explore
potential interactions between the mutations, the ANOVA
model was split along the APPtg? or NEP- factor. Data are
expressed as mean ± SEM, ns shows a non-significant
effect.
Results
Neprilysin Deficiency was Associated with Increased
Amyloid Pathology
Amyloid plaque load was studied in mouse brains via
immunohistochemistry utilizing the 4G8 antibody, which
recognizes both human and mouse Ab peptides. APPtg
mice exhibited small punctated and compacted amyloid
plaques, whereas, the number and size of amyloid plaques
were greater in the brains of doubly mutated NEP-APPtg
mice (Fig. 1). Concentrations of SDS- and formic acid
(FA)-soluble Ab40 and Ab42 were further quantified in
each mouse brain (Table 1). In SDS homogenates of WT
brains, the Ab40 concentration was 0.69 ± 0.05 nM,
whereas, Ab42 values did not exceed background levels.
Ab40 concentrations differed markedly between groups in
the following manner: WT \ NEP- \ APPtg \ NEP-
APPtg (Table 1). In the FA homogenates, however,
measurable Ab40 was only found in APPtg and NEP-
APPtg brains with levels in the latter genotype being
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Fig. 1 Neprilysin deficiency
exacerbates amyloid pathology
in mouse brains. Frontal brain
sections through the
hippocampal formation were
stained with the 4G8 antibody,
which recognizes both human
and murine Ab. APPtg mice
exhibited distinct amyloid
deposits but the amyloid plaque
load was highest in doubly-
mutated mice (NEP-APPtg)
combining chronic low
neprilysin levels and expression
of the AD-associated human
APP transgene
Table 1 Quantification of brain Ab concentrations
WT NEP- APPtg NEP-APPtg
SDS soluble
Ab40 (nM ± SEM) 0.69 ± 0.05 1.27 ± 0.09 2.07 ± 0.1 5.79 ± 0.25
Ab42 (pM ± SEM) Nd Nd Nd 1,067 ± 161
Formic acid soluble
Ab40 (nM ± SEM) Nd Nd 0.383 ± 0.026 1.049 ± 0.10
Ab42 (pM ± SEM) Nd Nd Nd 887 ± 290
Brain Ab levels (both murine- and transgenically expressed human-species) showed that lowered neprilysin levels or expression of AD-causing
human APP led to an accumulation of Ab in mouse brains
Levels of Ab40 and Ab42 were below detection sensitivity in the formic acid fraction of WT and neprilysin-deficient mice. Moreover, Ab42 was
not detected in brains of WT mice, confirming previous findings that these levels are too low for detection by ELISA [51, 52]. Finally, the entire
Ab content in brains of the APPtg mice represented Ab40, reflecting the mild amyloid pathology in our APPtg mouse line, when compared to
their NEP-APPtg littermates. The concentrations of SDS- and formic acid-soluble Ab40 in brains of NEP-APPtg mice were significantly higher
than the corresponding levels in the APPtg littermates (P \ 0.01 and \ 0.001, respectively)
Nd not detectable
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approximately 2.7 fold higher than in the APPtg brains.
Furthermore, no FA-soluble Ab42 was found in WT, NEP-
and APPtg brains (Table 1). As expected, neprilysin enzy-
matic activity was reduced in NEP- and NEP-APPtg mice
when compared to their WT or APPtg littermates (Fig. 2).
In addition, no statistical difference was found in the WT and
APPtg brains suggesting that over-expression of human APP
did not affect brain neprilysin activity (1-way ANOVA:
genotype P \ 0.0001, WT vs. NEP- P \ 0.0001, WT vs.
APPtg ns, WT vs. NEP-APPtg P \ 0.0001, APPtg vs. NEP-
APPtg P \ 0.0001, Fig. 2).
Neprilysin Deficiency Resulted in Worsening
of Hippocampus-Dependent Cognitive Functions
In the cued navigation task, all groups learned to find the
visible platform. In this task, independent of the NEP
expression level, the APP transgene was associated with a
small increase in escape latencies, while neprilysin defi-
ciency itself had no effect (repeated ANOVA: APPtg?
P \ 0.0055, NEP- ns, time P \ 0.0001, APPtg? 9
time ns, NEP- 9 time ns, NEP-APPtg ns, Fig. 3a, b). In
contrast, in the place navigation task, we found that the
effect of the APP transgene on escape performance
depended on neprilysin deficiency (Fig. 3c, d). The pres-
ence of the APP transgene was associated with significantly
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Fig. 2 Neprilysin enzymatic activity was significantly lower in
NEP- and NEP-APPtg brains when compared to their WT or APPtg
littermates (enzyme activity in WT brains was set at 100%). No
statistical difference was observed between the WT and APPtg
groups. ns not significant, ***P \ 0.0001
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Fig. 3 APP transgene effect
without (a, c) and with (b, d)
concomitant neprilysin
deficiency on training
performance in the Morris water
maze. a, b All groups learned
the cue navigation task. The
escape latencies (in seconds) of
each two consecutive trials were
calculated and the group
averages were built. Neprilysin
deficiency did not affect the
performance in the cue
navigation task, but
independently of the neprilysin
expression level the inheritance
of APP transgene was
associated with a small increase
in escape latencies. (for
significance levels see the
‘‘Results’’ section). c, d In the
place navigation task, the data
are suggestive of a NEP
deficiency dependent effect of
the APP transgene on escape
performance. The escape
latencies are built as above. The
APP transgene was associated
with significantly increased
escape latencies in neprilysin
deficient mice (d). In the
presence of normal neprilysin
levels (c) this difference was
much smaller and statistically
insignificant (for significance
levels see the ‘‘Results’’ section)
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increased escape latencies in NEP- mice (Fig. 3d), while in
the presence of normal neprilysin levels this difference was
statistically insignificant (Fig. 3c) (repeated ANOVA: AP-
Ptg? P \ 0.0023, NEP- ns, time P \ 0.0001, APPtg? 9
time ns, NEP- 9 time P \ 0.0749, NEP-APPtg ns; split
ANOVA APPtg?: in WT place ns; in NEP- P \ 0.0052,
Fig. 3c, d).
The genotype affected spatial measures directly related to
memory and cognition, as assessed in the probe trial
(Fig. 4). Performance during the probe trial, undertaken
following the MWM place navigation task, showed that all
mice searched preferentially in the target zone, thus indi-
cating successful spatial learning. Time spent in the target
zone further indicated an effect of neprilysin-deficiency on
spatial selectivity that was dependent on the APP transgene.
The NEP-APPtg mice exhibited a reduced selectivity for the
target zone when compared with their APPtg littermates
(repeated ANOVA: place P \ 0.0001, APPtg? 9 place ns,
NEP- 9 place ns, NEP-APPtg 9 place P \ 0.0790; split
ANOVA APPtg?: in WT place P \ 0.0045, APPtg? 9
place ns; in NEP- place P \ 0.0057, APPtg? 9 place
P \ 0.1068, Fig. 4a, b). Moreover, analysis of annulus
crossings, the most stringent measure of spatial selectivity,
confirmed that the APP transgene was associated with a loss
of spatial selectivity in the presence (Fig. 4d), but not
absence of (Fig. 4c), neprilysin deficiency (repeated
ANOVA: place P \ 0.0031, APPtg? 9 place P \ 0.1076,
NEP- 9 place ns, NEP-APPtg 9 place P \ 0.0228;
split ANOVA APPtg?: in WT place P \ 0.0080, AP-
Ptg? 9 place ns; in NEP- place P \ 0.1032, APPtg?
9 place P \ 0.0228, Fig. 4c, d). APPtg mice were unim-
paired in MWM testing, a result that can be explained with
the mild Ab pathology in our mouse line and in agreement to
previous results [18]. Fig. 4 seems to suggest such an
improvement in the NEP- animals. However, this trend was
statistically not significant (comparison of NEP?/? vs.
NEP- in the APPtg-: place P \ 0.0079, place 9 NEP-
P \ 0.1509). Probe trial measures were normalized to dis-
tance swum to avoid interference with differences in
swim speed.
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Fig. 4 APP transgene effect
without (a, c) and with (b, d)
concomitant neprilysin
deficiency on performances
during the probe trial. a, b The
spatial selectivity was assessed
by the percent of time spent in
the target zone area. The APP
transgene was associated with
reduced selectivity in the
presence (b) but not in the
absence (a) of neprilysin
deficiency suggesting a
neprilysin-deficiency dependent
APP effect (for significance
levels see the ‘‘Results’’
section). c, d According to
assessment of annulus
crossings, the most stringent
measure of spatial selectivity,
defined by the number of
crossings over the target area
and respective control annuli
per swam distance, the APP
transgene was associated with a
loss of spatial selectivity in the
presence (d) but not in the
absence (c) of neprilysin
deficiency (for significance
levels see the ‘‘Results’’ section)
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Neprilysin Deficiency Resulted in Worsening of CTA
Performance
Testing mice in the CTA required subjecting mice to water-
deprivation. Therefore, to avoid any possible behavioral
influences of previous training in the MWM and in order to
be able to test the mice in all behavioral tests at
±24 months of age, we decided to use a separate mouse
group for the CTA rather than using the same mice that
were tested in the MWM. Age-matched mice (n = 10 each
genotype), originating from the same parents as mice tested
in the previous behavioral tests were employed to examine
the hippocampus-independent associative memory in CTA
paradigm.
Body weight of the mice did not vary significantly
between groups during the course of the CTA test. More-
over, all groups drank comparable amounts of water during
the adaptation- and conditioning-phases and genotype did
not affect the amount of saccharin drunk during the con-
ditioning trial. 48 h after conditioning, mice were subjected
to the first choice test (Fig. 5, day 1), by presenting them
with one bottle containing saccharin solution and one bottle
filled with water. No differences in memory trace were
found between the genotype groups in the first choice test,
indicating that all groups learned the task successfully
(Fig. 5, day 1). The strength of the conditioned aversion
(P \ 0.001) and the speed of its extinction were signifi-
cantly different (genotype 9 days P \ 0.001) among the
genotype groups (Fig. 5). The APP transgene was associ-
ated with facilitated extinction of the associative memory.
During the subsequent weekly choice tests (Fig. 5, days 8,
15, 21, 28) an increase of aversion coefficient, i.e., memory
impairment, was observed in all groups. WT and NEP-
mice displayed an equally strong aversion against saccha-
rin, suggesting that neprilysin deficiency did not alter the
CTA performance. APPtg as well as NEP-APPtg doubly
mutated mice showed a significantly weaker conditioned
aversion in the choice tests with NEP-APPtg showing the
lowest CTA performance (ANOVA: genotype P \ 0.001,
WT vs. NEP- ns, WT vs. APPtg P \ 0.001, WT vs. NEP-
APPtg P \ 0.001, APPtg vs. NEP-APPtg P \ 0.01). Taken
together, these results show a negative effect of the APPtg
genotype on CTA performance, which is further worsened
by neprilysin deficiency.
Lastly, the avoidance of an intrinsic aversive bitter taste
was determined by offering the water-deprived mice qui-
nine solution or water. No difference between the four
groups was detected (P \ 0.48, not shown), confirming
that taste sensitivity did not differ between the groups.
Discussion
The findings described in this paper show that partial lack
of neprilysin, resembling the lowered neprilysin levels in
aged human brains, led to an enforced amyloid pathology
in the brain and to impairment of both hippocampal-
dependent and-independent cognitive performance.
Accumulation of Ab in the brain is associated with
memory impairment of AD patients. High Ab levels are
shown to induce synaptic dysfunction [1, 17, 24] and to
result in the formation of amyloid plaques, leading to
compromised neuronal integrity and function [25–27]. The
topological and spatial distribution of neprilysin suggests a
physiological role in Ab catabolism [7, 28]. In addition,
neprilysin is down-regulated in the hippocampus and
cerebral cortex during normal aging [29, 30] and in early
stages of AD development [10, 29, 31], thus linking an
inefficient Ab clearance from the brain and AD patho-
physiology. Moreover, neprilysin has been shown to be a
major peptidase capable of Ab degradation in vivo [8, 9].
An important contribution to understanding the mecha-
nisms of AD pathophysiology was achieved by generation of
transgenic models over-expressing APP in brain neurons.
Despite the importance of these mice in mimicking amyloid
plaque pathology associated with AD, it should be kept in
mind that not only Ab, but also APP and APP-proteolytic
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Fig. 5 Effects of APP transgene and neprilysin deficiency on
memory performance in the CTA. The aversion coefficient, a measure
of impairment of associative memory, defined as the percentage of
saccharin consumption divided by the total fluid intake, is depicted
over five choice tests. All genotype groups succeeded in CTA but
saccharin intake was significantly increased in the presence of the
APP transgene. Both APPtg and NEP-APPtg mice displayed a
significantly diminished conditioned aversion against saccharin
compared to NEP- and WT mice, with NEP-APPtg mice exhibiting
the poorest memory performance. Performance of NEP mice did not
differ from their WT littermates (for significance levels see the
‘‘Results’’ section)
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fragments are over-expressed and thus accumulate in the
brains of such models, making it difficult to assign the
observed effects to Ab only. This difficulty arises from
the fact that APP proteolytic fragments are implicated in
contradictory functions: they can be neurotoxic [32–34],
may impair LTP [35, 36], lead to neurodegeneration [37, 38]
and cognitive impairments [36, 37], while also being
reported to enhance LTP [39], to be neuroprotective [40] and
to up-regulate neprilysin activity [41].
A further complication arises from the fact that devia-
tions from physiological APP level may have negative
functional consequences. It was shown, in mice over-
expressing APP, that Ab rather than APP is involved in
synaptotoxicity as measured by assessment of synapto-
physin immunoreactivity [17]. Counter-intuitively, a
similar decrease in synaptophysin immunoreactivity,
impaired synaptic plasticity and deficits in cognitive
functions were also found in mice lacking APP [42–44]
and a defective memory performance was also reported in
mice over-expressing WT APP [45]. These data demon-
strate the complex role of APP and its photolytic fragments
in neuronal function.
Reports from several laboratories, including ours, show
that neprilysin degrades Ab without affecting APP
metabolism [13, 14, 18, 46, 47]. Therefore, in the present
study, by using mice with lower neprilysin activity we were
able to specifically target Ab without modification of APP
processing because APP processing is not changed by
neprilysin deficiency [14] or over-expression [18, 46, 47].
Therefore, APP transgenic mice that also carried one
defective Mme allele represent a unique experimental
model to analyze effects mediated by a sole elevation of
Ab on cognition. The reason for employing mice with only
a partial neprilysin deficiency, rather than mice with a total
lack of neprilysin, was that we aimed to recapitulate the
human situation as accurately as possible, in which a
reduction—but not elimination—of neprilysin is detected
in aged or AD brains. In the double-mutated mice (NEP-
APPtg), the neprilysin activity was reduced to approxi-
mately half of corresponding values in APPtg brains,
reflecting the reduction of neprilysin in brains of AD
patients [48, 49]. Moreover, we employed an APPtg mouse
line exhibiting a relatively mild phenotype, again to be able
to model the accumulation of Ab in brains of AD patients
over an extended period of time.
Biochemical analysis revealed that in comparison with
APPtg littermates, the double-mutated mice exhibited a
significant decrease in neprilysin enzymatic activity and an
elevation of brain Ab. To examine whether neprilysin
deficiency affects cognitive functions, mice were tested in
MWM and CTA tests, exemplifying hippocampus-depen-
dent spatial learning and memory and hippocampus-
independent associative memory, respectively.
In the open field (not shown) we found that motor and
motivational characteristics were indistinguishable from
each other. This finding is in concert with previous data
that APPtg and neprilysin-deficient mice are normal and
that the reduction of neprilysin enzymatic activity can be
well tolerated by the organism [6, 16] and with own data
that neprilysin heterozygous and homozygous mice were
very similar in behavioral tests [14].
In all cognitive behavioral tests, neprilysin-deficient
mice did not differ from WT controls. In the MWM test, all
groups of mice were able to find the location of both a
visible and a hidden platform. Moreover, NEP- mice
performed similarly to their WT littermates in the probe
trial, reconfirming their normal spatial memory and learn-
ing performance. In contrast, the combination of neprilysin
deficiency with APP over-expression in NEP-APPtg mice
was associated with behavioral impairment in the probe
trial, a finding that is in line with overt accumulation of
soluble and aggregated forms of Ab in brains of the dou-
ble-mutated animals. Therefore, inefficiency of Ab
removal from the brain due to a reduced neprilysin activity
led to the diminished performance in the hippocampus-
dependent MWM.
Our data are in line with reports showing that elevated
brain Ab levels in mice with neuronal expression of
mutated human APP or in neprilysin knock-out mice cause
a worsening of CTA [14, 22]. Combining neprilysin defi-
ciency and elevated APP expression in NEP-APPtg mice
proved most destructive for CTA performance. In agree-
ment with the MWM data, performances of WT and NEP-
mice in the CTA test were indistinguishable. Moreover, a
negative dominant effect of the APPtg genotype on CTA
performance was observed as reported earlier [18], which
was accentuated in the NEP-APPtg double-mutated mice.
As outlined for the MWM, these results indicate that
neprilysin deficiency and the consequent accumulation of
Ab resulted in the inability of the double-mutated mice to
perform normally in the CTA testing paradigm.
Recent data suggest that the levels of neprilysin sub-
strates, except for Ab, are unchanged in brains of
neprilysin knock-out mice [28], excluding the possibility
that observed effects in the NEP-APPtg mice may be due to
accumulation of those other neprilysin substrates. More-
over, Ab degradation by neprilysin is a down-stream event
after Ab generation and does not affect APP metabolism
[13, 14, 18, 46, 47, 50]. These data, in combination with
the fact that NEP- mice did not differ from WT littermates
in their performances in the MWM and CTA behavioral
tests, stress the specificity of the observed effects. They
also show that a worsening of memory performance of the
NEP-APPtg mice in these cognitive paradigms was caused
by accumulation of Ab in the brains of double-mutated
mice.
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We showed here that a partial reduction of neprilysin
activity and the consequent defective removal of Ab from
the brain led to exacerbation of amyloid pathology result-
ing in significant deficits of the NEP-APPtg mice in both
associative and reference memory tasks when compared to
their NEP- and APPtg littermates. These data are in
agreement with a report showing that a complete lack of
neprilysin at the site of synapses led to impaired synaptic
plasticity and behavioral performance [13], and are in line
with the reported selective reduction of neprilysin in spo-
radic AD, particularly in brain areas with a high plaque
burden [10, 11], and in normal aging [29].
Taken together, these data provide the unequivocal
evidence that even a partial neprilysin insufficiency, simi-
lar to the observed reduction of neprilysin activity in aging
brains, leads to an aggravation of amyloid pathology and to
cognitive impairments in vivo and furthermore emphasize
the importance of developing strategies to maintain phys-
iological levels of neprilysin activity during aging and in
AD therapy.
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